论文信息 - Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study. - 字舞流文

Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study.

F. Tempia | B. Borroni | L. Orsi | C. Costanzi | N. Mitro | D. Caruso | M. Manes | A. Brusco | L. Boccone | B. Paghera | A. Alberici | E. Premi | M. Ferrero | E. di Gregorio | M. Pasolini | C. Pani | A. Padovani

[1] F. Tempia,et al. Motor Deficits and Cerebellar Atrophy in Elovl5 Knock Out Mice , 2017, Front. Cell. Neurosci..

[2] D. Perani,et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38 , 2017, Annals of neurology.

[3] F. Tempia,et al. Clinical and neuroradiological features of spinocerebellar ataxia 38 (SCA38) , 2016, Parkinsonism & related disorders.

[4] F. Tempia,et al. ELOVL5 mutations cause spinocerebellar ataxia 38. , 2014, American journal of human genetics.

[5] H. Sasaki,et al. Usefulness of the Scale for Assessment and Rating of Ataxia (SARA) , 2008, Journal of the Neurological Sciences.

[6] Thomas E. Nichols,et al. Nonparametric permutation tests for functional neuroimaging: A primer with examples , 2002, Human brain mapping.

[7] M. Hallett,et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome , 1997, Journal of the Neurological Sciences.